Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.

"Conflict-of-interest disclosure: M.H. reports research funding from EDO-Mundipharma, Novartis, and Roche, and honoraria from AbbVie, BeiGene, Jazz, Janssen-Cilag, Stemline Menarini, and Takeda. C.D. reports honoraria from AbbVie, AstraZeneca, Kite, and Janssen. F.Z. reports honoraria from AbbVie, Janssen, Novartis, Amgen, Sobi, Grifols, Argenx, Takeda, and Gilead; research funding from Novartis, AbbVie, Janssen, Amgen, and Sobi; and serving on advisory boards for AbbVie, Novartis, Takeda, Grifols, and BeiGene. D.E.-S. reports honoraria from AbbVie, AstraZeneca, BeiGene, Janssen, Lily, Roche, and Takeda; conference/travel support from AbbVie, Novartis, and Roche; and serving on advisory boards for AbbVie, Astex Pharmaceuticals, AstraZeneca, BeiGene, Janssen, and Kyowa Kirin. W.D. reports institutional research funding from Merck, AstraZeneca, AbbVie, BeiGene, Octapharma, and DTRM, and serving on advisory boards for Merck, BeiGene, MEI Pharma, Alexion, and Octapharma. M.B. reports departmental financial support for educational purposes from Janssen, and individual sponsored travel to scientific workshop from Amgen and AbbVie. A.K. reports advisory boards for Janssen, Amgen, Bristol Myers Squibb (BMS)/Celgene, Roche, Kyowa Kirin, and Mundipharma. E.J. reports research support from Novartis, Pharmacyclics, Janssen, BeiGene, Daiichi Sankyo, and Celgene, and consulting for Bayer, ADC Therapeutics, Daiichi Sankyo, Imbrium, Merck, and Secura Bio. T.A.E. reports education honoraria from Roche and Kite; honoraria from Gilead, AbbVie, AstraZeneca, and Janssen; serving on advisory boards for Roche, Kite, Loxo Oncology, BeiGene, Incyte, and Secura Bio; research support from Gilead, AstraZeneca, and BeiGene; support for travel to scientific conferences from Roche, Gilead, AbbVie, and AstraZeneca; and serving on a steering committee for Loxo Oncology. D.R.-W. reports honoraria from AbbVie, AstraZeneca, BeiGene, and Janssen; conference/travel support from AbbVie, BeiGene, and Janssen; and serving on advisory boards for AstraZeneca and Janssen. T.K. reports consulting or an advisory role for Novartis, Jazz Pharmaceuticals, Pfizer, AbbVie/Genentech, Agios, Daiichi Sankyo/UCB Japan, Liberum, Sanofi, Servier, and Pinot Bio, and research funding from BMS, Celgene, Amgen, BioLineRx, Incyte, Genentech/AbbVie, Pfizer, Jazz Pharmaceuticals, AstraZeneca, Astellas Pharma, Ascentage Pharma, GenFleet Therapeutics, Cyclacel, Pulmotect, Cellenkos, GlycoMimetics, Astex Pharmaceuticals, Iterion Therapeutics, and Delta-Fly Pharma. N.P. reports honoraria from Takeda and serving on an advisory board for Clinigen. M.S.D. reports institutional research funding from AbbVie, AstraZeneca, Ascentage Pharma, Genentech, MEI Pharma, Novartis, Surface Oncology, and TG Therapeutics, and personal consulting income from AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, MingSight Pharmaceuticals, ONO Pharmaceuticals, Research to Practice, Secura Bio, TG Therapeutics, and Takeda. G.P., N.M., M.B., and T.V. report employment with AbbVie and may hold stock or other options. P.B.S. reports honoraria from Roche, Gilead, Kite, Janssen, AbbVie, AstraZeneca, BeiGene, and Incyte; serving on advisory boards for Roche, Kite, Janssen, AbbVie, AstraZeneca, BeiGene, Incyte, and Takeda; travel support to scientific conferences from Roche, Gilead, AbbVie, AstraZeneca, and BeiGene; and research funding from Roche. L.T. declares no competing financial interests."

"Acknowledgments: The authors thank the patients and their families, study coordinators, and support staff. Medical writing support was provided by Rohina Rubicz and Paul B. Card of Bio Connections LLC, funded by 10.13039/100006483AbbVie. Venetoclax is being developed in collaboration between AbbVie and Genentech. 10.13039/100006483AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, review, and approval of this publication."